SCHEMBL15026459

SCHEMBL15026459

COCCOC(=O)/C(=C/c1ccccc1Cl)C(C)=O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.54
KMT2A Q03164 4/20 0.54
LMNA P02545 2/20 0.54
KDM4E B2RXH2 2/20 0.54
HSP90AA1 P07900 2/20 0.54
TSHR P16473 2/20 0.45
MEN1 O00255 3/20 0.44
PLIN1 O60240 1/20 0.44
POLB P06746 1/20 0.44
PLIN5 Q00G26 1/20 0.44
ABHD5 Q8WTS1 1/20 0.44
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
CA4 P22748 1/20 0.44
CA7 P43166 1/20 0.44
NPSR1 Q6W5P4 1/20 0.39
ALDH1A1 P00352 1/20 0.38
HPGD P15428 1/20 0.38
GLO1 Q04760 1/20 0.38
MAOB P27338 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10605767 0.85 TSHR (0.47) MAPTKMT2ALMNAKDM4EHSP90AA1
SCHEMBL11546817 0.85 MAPT (0.55) MAPTKMT2ALMNAKDM4EHSP90AA1
SCHEMBL11546810 0.85 MAPT (0.55) MAPTKMT2ALMNAKDM4EHSP90AA1
SCHEMBL4778793 0.85 MEN1 (0.57) MAPTKMT2ALMNAKDM4EHSP90AA1
SCHEMBL4778791 0.85 MEN1 (0.57) MAPTKMT2ALMNAKDM4EHSP90AA1
SCHEMBL11549769 0.84 LMNA (0.64) MAPTKMT2ALMNAKDM4EHSP90AA1
SCHEMBL7242741 0.84 CYP1A2 (0.55) MAPTKMT2ALMNAKDM4EHSP90AA1
SCHEMBL7242738 0.84 CYP1A2 (0.55) MAPTKMT2ALMNAKDM4EHSP90AA1
SCHEMBL11549758 0.84 LMNA (0.64) MAPTKMT2ALMNAKDM4EHSP90AA1
SCHEMBL10899651 0.83 LMNA (0.49) MAPTKMT2ALMNAKDM4EHSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9284330-B2 1,4-dihydro-naphthyridine derivative and pharmaceutical composition and use thereof JIANGSU SIMOVAY PHARMACEUTICAL CO., LTD. (CN) 2016-03-15 US disclosed
US-20140364443-A1 1,4-DIHYDRO-NAPHTHYRIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION AND USE THEREOF JIANGSU SIMOVAY PHARMACEUTICAL CO., LTD. (CN) 2014-12-11 US disclosed
US-20140364443-A1 1,4-DIHYDRO-NAPHTHYRIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION AND USE THEREOF JIANGSU SIMOVAY PHARMACEUTICAL CO., LTD. (CN) 2014-12-11 US disclosed
WO-2013083070-A1 1, 4-DIHYDRO-NAPHTHYRIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION AND USE THEREOF 江苏先声药业有限公司 (CN) 2013-06-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140364443-A1 1,4-DIHYDRO-NAPHTHYRIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION AND USE THEREOF ACHE, BACE1, CACNA1D MAPT 181/4885KMT2A 3555/4885LMNA 714/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.